Concepts (111)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tuberous Sclerosis | 1 | 2021 | 31 | 0.710 |
Why?
|
| Angiomyolipoma | 1 | 2021 | 17 | 0.710 |
Why?
|
| Critical Illness | 6 | 2023 | 346 | 0.590 |
Why?
|
| Education, Medical | 1 | 2020 | 252 | 0.530 |
Why?
|
| Kidney Neoplasms | 1 | 2021 | 557 | 0.490 |
Why?
|
| Internship and Residency | 2 | 2020 | 1134 | 0.420 |
Why?
|
| Multiple Organ Failure | 3 | 2023 | 60 | 0.410 |
Why?
|
| Resuscitation | 2 | 2023 | 131 | 0.350 |
Why?
|
| Intensive Care Units, Pediatric | 4 | 2022 | 117 | 0.280 |
Why?
|
| Child | 10 | 2023 | 7621 | 0.270 |
Why?
|
| Respiration, Artificial | 2 | 2022 | 425 | 0.270 |
Why?
|
| Iron | 2 | 2025 | 179 | 0.250 |
Why?
|
| Acute Kidney Injury | 1 | 2020 | 341 | 0.240 |
Why?
|
| Manganese | 1 | 2025 | 57 | 0.220 |
Why?
|
| Systemic Inflammatory Response Syndrome | 2 | 2022 | 60 | 0.220 |
Why?
|
| Autotrophic Processes | 1 | 2024 | 1 | 0.220 |
Why?
|
| Chromatiaceae | 1 | 2024 | 5 | 0.220 |
Why?
|
| Cation Transport Proteins | 1 | 2025 | 70 | 0.220 |
Why?
|
| Sulfur | 1 | 2024 | 30 | 0.210 |
Why?
|
| Fluid Therapy | 2 | 2023 | 67 | 0.210 |
Why?
|
| Sulfides | 1 | 2024 | 69 | 0.210 |
Why?
|
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2023 | 10 | 0.190 |
Why?
|
| Abatacept | 1 | 2023 | 88 | 0.190 |
Why?
|
| Shock, Septic | 1 | 2023 | 125 | 0.180 |
Why?
|
| Shewanella | 1 | 2021 | 3 | 0.180 |
Why?
|
| Hypernatremia | 1 | 2021 | 9 | 0.180 |
Why?
|
| Brain Diseases | 1 | 2023 | 193 | 0.180 |
Why?
|
| Child, Hospitalized | 1 | 2022 | 41 | 0.170 |
Why?
|
| Knowledge | 1 | 2020 | 30 | 0.160 |
Why?
|
| Intestinal Mucosa | 1 | 2025 | 824 | 0.160 |
Why?
|
| Myocarditis | 1 | 2020 | 62 | 0.160 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2021 | 127 | 0.160 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2021 | 220 | 0.160 |
Why?
|
| Herpes Simplex | 1 | 2021 | 203 | 0.150 |
Why?
|
| Education, Distance | 1 | 2020 | 25 | 0.150 |
Why?
|
| Bacterial Proteins | 2 | 2024 | 922 | 0.150 |
Why?
|
| Sepsis | 1 | 2023 | 389 | 0.140 |
Why?
|
| Hospital Mortality | 3 | 2022 | 485 | 0.140 |
Why?
|
| Humans | 17 | 2025 | 95992 | 0.130 |
Why?
|
| Kidney Transplantation | 1 | 2023 | 882 | 0.120 |
Why?
|
| Curriculum | 1 | 2020 | 616 | 0.120 |
Why?
|
| Atrial Fibrillation | 1 | 2020 | 444 | 0.110 |
Why?
|
| Pediatrics | 1 | 2020 | 399 | 0.110 |
Why?
|
| Adolescent | 6 | 2022 | 9878 | 0.110 |
Why?
|
| Clinical Competence | 1 | 2020 | 858 | 0.100 |
Why?
|
| Child, Preschool | 3 | 2022 | 3969 | 0.100 |
Why?
|
| Retrospective Studies | 6 | 2022 | 10307 | 0.100 |
Why?
|
| Age Factors | 2 | 2022 | 1959 | 0.090 |
Why?
|
| Infant, Newborn | 2 | 2021 | 2611 | 0.080 |
Why?
|
| Infant | 2 | 2022 | 3359 | 0.080 |
Why?
|
| Critical Care | 2 | 2023 | 448 | 0.070 |
Why?
|
| Female | 8 | 2023 | 49980 | 0.070 |
Why?
|
| Prevalence | 1 | 2020 | 1355 | 0.060 |
Why?
|
| Hemochromatosis | 1 | 2025 | 12 | 0.060 |
Why?
|
| Male | 6 | 2025 | 45792 | 0.060 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 1880 | 0.060 |
Why?
|
| Intestinal Absorption | 1 | 2025 | 126 | 0.050 |
Why?
|
| Photosynthesis | 1 | 2024 | 58 | 0.050 |
Why?
|
| Electrons | 1 | 2024 | 51 | 0.050 |
Why?
|
| Nootropic Agents | 1 | 2003 | 12 | 0.050 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2003 | 49 | 0.050 |
Why?
|
| Down Syndrome | 1 | 2003 | 53 | 0.050 |
Why?
|
| Indans | 1 | 2003 | 37 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2023 | 136 | 0.050 |
Why?
|
| Delayed Graft Function | 1 | 2023 | 16 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2020 | 2498 | 0.050 |
Why?
|
| Piperidines | 1 | 2003 | 171 | 0.050 |
Why?
|
| Cognition Disorders | 1 | 2003 | 244 | 0.040 |
Why?
|
| Time Factors | 1 | 2020 | 5593 | 0.040 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2022 | 67 | 0.040 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2021 | 16 | 0.040 |
Why?
|
| Acyclovir | 1 | 2021 | 110 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2021 | 393 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2025 | 2160 | 0.040 |
Why?
|
| Risk Factors | 1 | 2020 | 5992 | 0.040 |
Why?
|
| Recurrence | 1 | 2023 | 1231 | 0.040 |
Why?
|
| Consensus | 1 | 2021 | 372 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2020 | 398 | 0.040 |
Why?
|
| Kidney Failure, Chronic | 1 | 2023 | 432 | 0.040 |
Why?
|
| Cell Membrane | 1 | 2021 | 687 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2022 | 816 | 0.030 |
Why?
|
| Logistic Models | 1 | 2022 | 1273 | 0.030 |
Why?
|
| Simulation Training | 1 | 2020 | 108 | 0.030 |
Why?
|
| Machine Learning | 1 | 2021 | 348 | 0.030 |
Why?
|
| Hypoxia | 1 | 2023 | 681 | 0.030 |
Why?
|
| Comorbidity | 1 | 2022 | 1017 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2022 | 460 | 0.030 |
Why?
|
| Electrocardiography | 1 | 2020 | 559 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2025 | 2534 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2021 | 504 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2025 | 1729 | 0.030 |
Why?
|
| Oxygen | 1 | 2022 | 781 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2023 | 2885 | 0.030 |
Why?
|
| Phenotype | 1 | 2023 | 2575 | 0.030 |
Why?
|
| Registries | 1 | 2021 | 998 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2022 | 3115 | 0.030 |
Why?
|
| Hospitalization | 1 | 2021 | 946 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2021 | 1275 | 0.030 |
Why?
|
| Pregnancy | 1 | 2021 | 3239 | 0.030 |
Why?
|
| Adult | 3 | 2020 | 28636 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2020 | 4690 | 0.020 |
Why?
|
| Mice | 1 | 2025 | 12525 | 0.020 |
Why?
|
| Young Adult | 1 | 2020 | 7034 | 0.020 |
Why?
|
| Middle Aged | 2 | 2023 | 28299 | 0.020 |
Why?
|
| Animals | 1 | 2025 | 28901 | 0.010 |
Why?
|
| Language Development Disorders | 1 | 2003 | 24 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2003 | 857 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2003 | 548 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2003 | 1966 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2003 | 1792 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2003 | 9228 | 0.010 |
Why?
|